主页 > 医学前沿 >
【drug-news】科万斯与药明康德合资计划流产
Monday September 29, 8:42 am ET
Covance, Wuxy Pharmatech abandon plans for Chinese preclinical research services venture
PRINCETON, N.J. (AP) -- Covance Inc. and WuXi Pharmatech announced Monday they are abandoning plans to build a joint venture for preclinical contract research services in China.
Drug development services provider Covance and WuXi Pharmatech, a pharmaceutical, biotechnology and medical device research and development outsourcing company, gave no reason for abandoning the 50-50 venture.
WuXi said it will move on its original plan to build a 323,450-square-foot facility in Suzhou, China, that is due to open in the second half of 2009. The building will be used to offer preclinical services and toxicology work. [标签:content1][标签:content2]
阅读本文的人还阅读：
作者:admin@医学,生命科学 2011-04-25 05:11
医学,生命科学网